Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 87.86M P/E - EPS this Y 128.30% Ern Qtrly Grth -
Income -3.4M Forward P/E 64.80 EPS next Y 46.20% 50D Avg Chg 7.00%
Sales 51.66M PEG 2.47 EPS past 5Y - 200D Avg Chg 21.00%
Dividend N/A Price/Book 18.95 EPS next 5Y 15.00% 52W High Chg -34.00%
Recommedations 2.00 Quick Ratio 0.62 Shares Outstanding 13.59M 52W Low Chg 73.00%
Insider Own 25.56% ROA -6.93% Shares Float 4.89M Beta 0.46
Inst Own 50.57% ROE -432.46% Shares Shorted/Prior 327.73K/48.43K Price 6.48
Gross Margin 44.27% Profit Margin -6.58% Avg. Volume 9,067 Target Price -
Oper. Margin 9.45% Earnings Date Dec 10 Volume 7,138 Change 0.00%
About Champions Oncology, Inc.

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Champions Oncology, Inc. News
11/04/24 Champions Oncology (NASDAQ:CSBR) shareholders have endured a 61% loss from investing in the stock three years ago
10/16/24 Champions Oncology Announces Agreement with Weill Cornell Medicine
10/09/24 Champions Oncology Inc (CSBR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
10/09/24 Champions Oncology Inc (CSBR) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...
09/24/24 Champions Oncology (NASDAQ:CSBR) Is In A Strong Position To Grow Its Business
09/11/24 Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
09/09/24 Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
08/12/24 This Champions Oncology Insider Increased Their Holding By 14% Last Year
07/18/24 Champions Oncology Reports Quarterly Revenue of $14.0 Million
07/11/24 Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
06/04/24 Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
08:30 AM Champions Oncology (NASDAQ:CSBR) shareholders have endured a 53% loss from investing in the stock three years ago
04/17/24 Will Champions Oncology (NASDAQ:CSBR) Spend Its Cash Wisely?
03/19/24 Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Call Transcript
03/12/24 Champions Oncology Reports Quarterly Revenue of $12.0 Million
03/07/24 Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation
03/06/24 Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024
03/05/24 Pleasing Signs As A Number Of Insiders Buy Champions Oncology Stock
12/14/23 Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call Transcript
12/12/23 Champions Oncology Reports Quarterly Revenue of $11.6 Million
CSBR Chatroom

User Image Bulltrader988 Posted - 1 week ago

$CSBR next ones https://www.championsoncology.com/events

User Image Bulltrader988 Posted - 2 weeks ago

$CSBR good week so far

User Image Bulltrader988 Posted - 2 weeks ago

$CSBR next event: SITC 2024 November 6 - 10 Houston, Tx https://www.championsoncology.com/events

User Image Bulltrader988 Posted - 2 weeks ago

$CSBR https://www.accesswire.com/932325/champions-oncology-announces-agreement-with-weill-cornell-medicine

User Image Bulltrader988 Posted - 10/24/24

$CSBR waking up?

User Image OnlythedareWins Posted - 09/30/24

$CSBR where is the 5.3 ?

User Image Bulltrader988 Posted - 09/23/24

$CSBR bloody day here

User Image Fullratio Posted - 2 months ago

$CSBR debt fell by 15% YoY and by 4.3% QoQ: https://fullratio.com/stocks/nasdaq-csbr/champions-oncology

User Image Fullratio Posted - 2 months ago

$CSBR total assets has declined by 17% year-on-year and by 4.6% since the previous quarter: https://fullratio.com/stocks/nasdaq-csbr/champions-oncology

User Image RomeoPapa Posted - 2 months ago

$CSBR testing MA200. Interesting.

User Image tradingtwenty Posted - 2 months ago

Top 5 stocks by highest volume percent change (today vs 3-month average): $GV 234574.81% 🔥 $TNON 176589.27% $MNPR 67923.72% $CSBR 32526.80% $OBLG 28104.40% Link: https://tradingtwenty.com/dashboard/trending/past

User Image Stocksrunner Posted - 2 months ago

Analysts are bullish on $AURA $CSBR $FSLR $KIM are you ready for the potential gains? 📈 Check your portfolio and stay ahead of the curve! https://stocksrunner.com/posts/1135

User Image RomeoPapa Posted - 2 months ago

$CSBR some interest is showing up

User Image RomeoPapa Posted - 2 months ago

$CSBR another SL raid

User Image DonCorleone77 Posted - 2 months ago

$ROKU $BILL $PCH $CSBR $DEO TOP 5 ANALYST UPGRADES: -- Wolfe Research upgraded Roku (ROKU) to Outperform from Peer Perform with a $93 price target. Amid industry and Roku-specific fears about connected TV, or CTV, ad sales, management's rising focus on monetization supports acceleration and "should bury the profitability debate," says the firm, which lifted the firm's estimates above consensus. -- Exane BNP Paribas upgraded Bill (BILL) to Outperform from Neutral with a $90 price target. The company is investing in suppliers' go-to-market, which will generate sustainable take-rate expansion, the firm tells investors in a research note. -- BofA upgraded PotlatchDeltic (PCH) to Buy from Neutral with a $51 price target. Fundamental catalysts may be lacking in the near-term, but PotlatchDeltic offers 20%-plus total upside potential based on the firm's price target. -- Craig-Hallum upgraded Champions Oncology (CSBR) to Buy from Hold with an unchanged price target of $6. Champions' Q1 results showed "another positive step towards recovery," with revenues up 12% year-over-year and both adjusted EBITDA and EPS "jumping materially sequentially." -- BofA upgraded Diageo (DEO) to Buy from Neutral with a price target of 2,800 GBp, up from 2,600 GBp. After a challenging two years consensus forecasts "seem low enough now," the firm tells investors in a research note.

User Image Sunny_24 Posted - 2 months ago

$csbr boom.... 20% locked, nice.

User Image YouVSYou Posted - 2 months ago

$csbr most volume all year in one day Needs to break 5.34 and hold $5

User Image GSP Posted - 2 months ago

$CSBR $OBLG $MNPR $GRRR

User Image OpenOutcrier Posted - 2 months ago

$CSBR (+17.0% pre) Champions Oncology Non-GAAP EPS of $0.11 beats by $0.14, revenue of $14.06M beats by $0.83M - SA https://ooc.bz/l/42227

User Image GSP Posted - 2 months ago

Gap play watch list for today (con't): $MNPR $CSBR $GRRR $OBLG

User Image tradingtwenty Posted - 2 months ago

Top pre-market stock gainers: $TNON $SMFL $NITO $SUNE $CSBR 🔥 Link: https://tradingtwenty.com/dashboard/trending/past

User Image YouVSYou Posted - 2 months ago

$oblg the cult has its shot again to send it to $6 If 3.60 holds Let’s see $mnpr $csbr $smfl $tnon

User Image cjstocksup Posted - 2 months ago

$CSBR Great investment stock IMO. Over 50% of the shares are owned by institutions and insiders. Insider buys in the past 12 months have been higher than the current PPS and it was raised to a BUY today.

User Image DaBullRunner Posted - 2 months ago

$IMRX stop doubting me folks This is dirt cheap at current levels And shouldn’t be under $2 imo This has the potential to be double digits You seen me pound the tables at $SMMT while it was in the 1’s and now it just hit $24.99👇💰💰 And you all ignored me 🤦🏻‍♂️ Again, please do not ignore this ticker IMRX 🙏 $CSBR $NITO $SMFL

User Image Wolfpackcommunity Posted - 2 months ago

$CSBR pushing a little

User Image Thestocktraderhubzee Posted - 2 months ago

$CSBR Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6

User Image RomeoPapa Posted - 2 months ago

$CSBR Revenue growth: The company reported a 12% increase in revenue to $14.1 million. Profitability: Champions returned to profitability with $1.3 million in net income, compared to a loss of $2.6 million the previous year. Cost reductions: Significant operational cost improvements, lowering total expenses by 15.8%. Margin improvement: Gross margins rose to 50%, driven by operational efficiencies and revenue growth​.

User Image BongJamesBong Posted - 2 months ago

$CSBR Also watching: Shares of Champions Oncology, Inc. (NASDAQ:CSBR) rose sharply in today's pre-market trading reported better-than-expected financial results for the first quarter on Wednesday. The company reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of a loss of $0.3 per share. Champions Oncology shares jumped 13.5% to $4.55 in the pre-market trading.

User Image WallStKiller Posted - 2 months ago

$CSBR Have a very good feeling about thisone today,Just on watch!

User Image Profitrip Posted - 2 months ago

$CSBR $4.6> the 50ema on 15 min chart

Analyst Ratings
Craig-Hallum Buy Sep 12, 24
Craig-Hallum Hold Mar 13, 24
Roth MKM Buy Sep 22, 23
Roth Capital Buy Mar 15, 21
Benchmark Speculative Buy Nov 18, 19
Roth Capital Buy Sep 20, 19
Janney Montgomery Scott Neutral Jul 24, 19
Craig-Hallum Buy Jul 17, 18
Dawson James Buy May 15, 18
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mendelson Daniel Newman Director Director Jan 12 Buy 6.50 1,000 6,500 198,625 01/16/24
Mendelson Daniel Newman Director Director Jan 11 Buy 6.27 2,000 12,540 197,625 01/12/24
Mendelson Daniel Newman Director Director Jan 10 Buy 6.31 2,944 18,577 195,625 01/11/24
Mendelson Daniel Newman Director Director Jan 09 Buy 6.25 3,000 18,750 192,681 01/10/24
Mendelson Daniel Newman Director Director Jan 08 Buy 6.15 1,000 6,150 189,681 01/09/24
Mendelson Daniel Newman Director Director Dec 21 Buy 4.92 2,500 12,300 183,181 12/26/23
Mendelson Daniel Newman Director Director Dec 20 Buy 4.82 2,100 10,122 180,681 12/21/23
Mendelson Daniel Newman Director Director Dec 19 Buy 4.75 5,000 23,750 178,581 12/20/23
Mendelson Daniel Newman Director Director Sep 29 Buy 6.16 4,000 24,640 173,581 10/16/23
Mendelson Daniel Newman Director Director Sep 28 Buy 6.22 5,000 31,100 169,581 10/16/23
Mendelson Daniel Newman Director Director Sep 27 Buy 5.95 1,500 8,925 164,581 10/16/23
Mendelson Daniel Newman Director Director Oct 11 Buy 6.40 5,000 32,000 163,081 10/13/23
Mendelson Daniel Newman Director Director Oct 06 Buy 6.48 1,530 9,914 156,981 10/10/23
Mendelson Daniel Newman Director Director Oct 05 Buy 6.47 2,000 12,940 155,451 10/06/23
Mendelson Daniel Newman Director Director Oct 03 Buy 6.30 2,500 15,750 148,451 10/04/23
Mendelson Daniel Newman Director Director Oct 04 Buy 6.40 5,000 32,000 153,451 10/04/23
Mendelson Daniel Newman Director Director Sep 26 Buy 5.65 5,000 28,250 145,951 09/27/23
Mendelson Daniel Newman Director Director Sep 19 Buy 5.28 5,000 26,400 128,121 09/25/23
Mendelson Daniel Newman Director Director Sep 20 Buy 5.51 4,018 22,139 132,139 09/25/23
Mendelson Daniel Newman Director Director Sep 21 Buy 5.51 5,000 27,550 137,139 09/25/23
Mendelson Daniel Newman Director Director Sep 22 Buy 5.50 3,812 20,966 140,951 09/25/23